There was also an increase in PLP45–53:HLA-A3 CD20+ CD8+ T cells in MS patients compared to controls that was nonsignificant (18.7 ± 11.1% and 7.9 ± 3.8%, respectively; P = 0.08). This evidence concerns the gene CD8A and myeloid sarcoma.